-
Express treatment of advanced lung cancer, tumor suppressor gene therapy/Keytruda combination obtained FDA fast track qualification
Time of Update: 2022-01-08
S. FDA has granted the gene therapy Reqorsa Fast Track Designation (FTD), and Merck (MSD)'s blockbuster PD-1 inhibitor Keytruda (pembrolizumab, pembrolizumab) Combined use to treat patients with stage III or IV non-small cell lung cancer (NSCLC) whose histologically confirmed unresectable .
-
BJU Int: After radical prostatectomy, which patients need surgical intervention for urinary incontinence?
Time of Update: 2022-01-08
Recently, researchers from the United States published an article in "BJU Int" to investigate whether the urinary incontinence and distress scores reported by patients after radical prostatectomy will lead to subsequent urinary incontinence surgical interventions .
-
BMC Cancer: For locally advanced esophageal cancer, such as cT1N+ and cT2Nany, is neoadjuvant therapy or adjuvant therapy better?
Time of Update: 2022-01-08
Differences in OS of different treatment options in the adjuvant therapy (AT) group OS difference of different treatment options in the adjuvant treatment (AT) group OS difference of different treatment options in the adjuvant treatment (AT) group In summary, studies have shown that NT has no obvious advantage over AT in patients with cT1N+ and cT2N any esophageal cancer .
-
Express precise treatment of non-small cell lung cancer, FDA granted EGFR inhibitor breakthrough therapy designation
Time of Update: 2022-01-08
▎Editor of WuXi AppTec's content team On January 4, 2022, Cullinan Oncology announced that the US FDA has granted the epidermal growth factor receptor (EGFR) inhibitor CLN-081 breakthrough therapy designation for the treatment of previous systemic drugs.
-
J Cancer Res Clin Oncol: Real-world data from the First Hospital of Guangzhou Medical University found that Sintilimab (sintilimab) combined with paclitaxel + platinum may further improve the survival of advanced lung squamous cell carcinoma
Time of Update: 2022-01-08
Studies have shown that Sintilizumab+TP and Sintilizumab+GP have similar efficacy in the first-line treatment of patients with advanced or metastatic sqNSCLC .
Studies have shown that Sintilizumab+TP and Sintilizumab+GP have similar efficacy in the first-line treatment of patients with advanced or metastatic sqNSCLC .
-
Jinan launches universal vaccination of four-valent HPV vaccine for school-age girls in the city
Time of Update: 2022-01-08
Director Miao Zhiying introduced that at present, more than two-thirds of the seventh-grade girls in the Ganshiqiao Community Health Service Center have been vaccinated against HPV , but there are still a small number of parents of children who are still hesitating and do not know how to choose.
-
JAMA Netw Open: Professor Haiqiang Mai’s team from Zhongzhong confirmed that concurrent radiotherapy and chemotherapy based on nedaplatin can be used as an effective treatment plan for patients with stage II-IVB nasopharyngeal carcinoma
Time of Update: 2022-01-08
Prognostic difference analysisPrognostic difference analysisWe performed OS, PFS, DMFS, and LRFS subgroup analysis of patients stratified by the following covariates: gender (male or female), age (45 years or ≥45 years), KPS score (70-80 or 90-100) ), disease stage (II-III or IVA-B) .
-
Guideline Recommendations: Technical guidelines for the application of biomarkers in the clinical development of anti-tumor drugs
Time of Update: 2022-01-08
Biomarkers are not only widely used in clinical practice, but their value in the research and development of anti-tumor drugs has also become increasingly prominent, and has gradually become an extremely important, even indispensable, research and development tool in the development of anti-tumor drugs .
-
European Radiology: How to obtain the molecular subtypes of diffuse glioma non-invasively?
Time of Update: 2022-01-08
Recently, a study published in the journal European Radiology developed an evaluation system based on radiomics and DCNN to predict the molecular subtypes of diffuse gliomas, and explored the correlation between radiomics and DCNN features.
-
Today, BeiGene's new indication for anti-PD-1 antibody is expected to be approved in the near future; the NGS-based CaptHPV liquid biopsy method can be used for the detection of different types of HPV tumors
Time of Update: 2022-01-08
The NGS-based CaptHPV liquid biopsy method can be used for the detection of different types of HPV tumorsRecently, the research team of the Dakar Cancer Institute in Senegal found that ct-HPV DNA detection and the virus pattern characteristics of HPV-related invasive cancer can be achieved by analyzing standard blood samples, regardless of tumor type and virus genotype, all have high levels Sensitivity and specificity .
-
PNAS: A drop of blood may be able to quickly detect early human lung cancer
Time of Update: 2022-01-08
Lung cancer is the main cause of death in cancer patients. It is only diagnosed in the late stage of the disease , and the survival rate of patients at this time is often low; most early lung cancers
-
Science Advances: Peking University Yin Yuxin's team develops a new method of AI-assisted metabolomics diagnosis of pancreatic cancer
Time of Update: 2022-01-08
Recently, Professor Ki Bun new team at Peking University School of Basic Medical Science Advances Online published a report entitled: Metabolic and Detection Systems Analyzes of pancreatic ductal adenocarcinoma through Machine Learning, lipidomics, and Multi-OMICS research papers .
-
Ther Adv Med Oncol: In patients with advanced pancreatic cancer who failed FOLFIRINOX treatment, GnP (gemcitabine + albumin-bound paclitaxel) is a feasible treatment measure
Time of Update: 2022-01-08
Therefore, a team from South Korea has carried out relevant studies to evaluate the efficacy of GnP (gemcitabine + albumin-bound paclitaxel) treatment after the progress of the first-line FOLFIRINOX regimen in patients with advanced pancreatic cancer .
-
Nature: Significant progress!
Time of Update: 2022-01-08
In other words, based on our research results, people would think that a diet low in palmitic acid Can effectively slow down the metastasis process, but to determine this requires more research work .
-
BMC Cancer: The team of Academician Xu Binghe analyzed the clinicopathological characteristics and survival prognosis of patients with metastatic breast cancer with simultaneous lung metastasis in the Han population in China
Time of Update: 2022-01-08
Therefore, the team of Academician Xu Binghe from the Tumor Hospital of the Chinese Academy of Medical Sciences conducted relevant research to analyze the clinicopathological characteristics and prognosis of patients with metastatic breast cancer with simultaneous lung metastasis (BCLM) in the Han population in China .
-
JAMA Surg: The effect of thyroid lobectomy vs. total resection on the quality of life of patients with thyroid cancer after surgery
Time of Update: 2022-01-08
For patients with differentiated thyroid cancer with a moderate to low risk of recurrence, the long-term postoperative quality of life of the patient has nothing to do with the scope of surgical resection.
-
Drinking and blushing is a genetic disease that greatly increases the risk of cancer. Will gene therapy be a savior?
Time of Update: 2022-01-08
Regarding ALDH2 gene mutations as a common genetic disease that leads to a significant increase in the risk of cancer, AAV gene therapy can enhance the activity of ALDH2 in the liver, which can prevent the risk of cancer in people who drink and blush and often drink alcohol .
-
Front Oncol: Previous anti-vascular treatment may affect the PFS of late-line Anlotinib in the treatment of advanced lung cancer, but does not affect OS and ORR
Time of Update: 2022-01-08
Guide to lung cancer blood vesselsThe study retrospectively collected clinical data on the use of Anlotinib in the treatment of LC patients, and divided the patients into group A (anlotinib treatment after failure of previous anti-angiogenic drugs) and group B (no anti-angiogenic drug treatment in the past) .
-
Cancer Cell: Fan Jia/Zhou Hu and others draw a panoramic view of the multi-omics molecular features of intrahepatic cholangiocarcinoma
Time of Update: 2022-01-08
On December 30, 2021, Academician Fan Jia of Zhongshan Hospital Affiliated to Fudan University, Researcher Zhou Hu of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Researcher Gao Daming of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, jointly published the title: Proteogenomic in Cancer Cell, a top international oncology journal characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma .
-
A picture to understand China PD-1/PD-L1 2021.12
Time of Update: 2022-01-08
Is expected in 2022 will have a variety of PD-1 / PD-L1 product is approved, the cornerstone for example, complex macros, and so on Kerry in 2022Non-small cell lung cancer : MSD, Hengrui, Baekje, Cinda have been approved as first-line squamous cell carcinoma and adenocarcinoma, and AZ is the only company in consolidation treatment .
